- Home
- NRXS vs LIXT Comparison
NRXS vs LIXT Comparison
Compare NRXS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | LIXT |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 25.4M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRXS | LIXT |
|---|---|---|
| Price | $3.90 | $4.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 854.7K | 83.3K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,362,320.00 | N/A |
| Revenue This Year | $31.05 | N/A |
| Revenue Next Year | $137.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.89 | N/A |
| 52 Week Low | $1.33 | $0.64 |
| 52 Week High | $6.20 | $6.26 |
Technical Indicators
Market Signals| Indicator | NRXS | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 69.03 | 47.15 |
| Support Level | $2.63 | $3.95 |
| Resistance Level | $4.25 | $4.34 |
| Average True Range (ATR) | 0.34 | 0.29 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 78.57 | 61.05 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.